Today's Rundown GSK's anti-BCMA drug hits goal in pivotal multiple myeloma test Immuno-oncology vet Humphrey bids CytomX adieu AstraZeneca pays Sobi $95M for priority review voucher Scorpion toxin uncovers insights into pain that could inspire non-opioid treatments Single-cell sequencer 10x Genomics files for $100M Nasdaq IPO EuroBiotech Report—Merck-Themis, Juvenescence financing, GSK filing and NuCana fail FiercePharmaAsia—A Pfizer warning?; Anemia race in Asia; Biotechs’ support for Chinese scientists Chutes & Ladders—Garraway will take over as Roche's next CMO Featured Story | | | Friday, August 23, 2019 A phase 2 trial of GlaxoSmithKline’s BCMA drug has hit its primary endpoint, keeping Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year. |
|
|
Top Stories Friday, August 23, 2019 Rachel Humphrey, M.D., who joined CytomX as chief medical officer, has made her exit. Her tenure at the probody biotech ended on Monday. CytomX gave no reason for Humphrey’s departure in a brief SEC filing Monday. Thursday, August 22, 2019 AstraZeneca has struck a $95 million deal to buy a FDA priority review voucher from Swedish Orphan Biovitrum. The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets. Friday, August 23, 2019 A team of researchers discovered a toxin from the venom of the Australian black rock scorpion triggers pain but not inflammation. The mechanism by which it achieves this could inspire treatments that block the inflammation that triggers chronic pain. Friday, August 23, 2019 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG. The maker of single-cell sequencing hardware hopes to expand the installed base of its Chromium instruments. Thursday, August 22, 2019 In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. Friday, August 23, 2019 Is Pfizer's mature drugs' decline in China an ill omen for other multinational pharmas? AstraZeneca and GlaxoSmithKline are racing their oral anemia drugs to China and Japan. Biomedical leaders voice concerns over "a climate of fear" created by the U.S. government's crackdown on IP theft. Friday, August 23, 2019 Eli Lilly’s Garraway pegged as newest chief medical officer at Roche; Ousted AveXis CSO Kaspar denies wrongdoing in data scandal; Longtime NICE chief Dillon set to exit. Resources Sponsored by: Alexander Group From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation. Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: BBK Worldwide The Study Voices survey challenges the myth that physicians won’t refer patients to clinical trials, and it identifies opportunities to engage physicians as partners in the enrollment process. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA BioImmersion: Biotech for the Non-Scientist October 23-25, 2019 | Chicago, IL 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 